Clinical trial NCT05832593 - References

Laryngeal Squamous Cell Carcinoma — Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.

Citation(s)

•   Avinash Tejasvi ML, Maragathavalli G, Putcha UK, Ramakrishna M, Vijayaraghavan R, Anulekha Avinash CK
  Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. Indian J Pathol Microbiol. 2020 Oct-Dec;63(4):538-543. doi: 10.4103/IJPM.IJPM_964_19.
•   Bohanes P, Labonte MJ, Lenz HJ
  A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer. 2011 Sep;10(3):157-64. doi: 10.1016/j.clcc.2011.03.024. Epub 2011 Apr 28.
•   Chen S, Zhang J, Wang R, Luo X, Chen H
  The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer. 2010 Oct;70(1):63-70. doi: 10.1016/j.lungcan.2010.05.010. Epub 2010 Jun 11.
•   Fasunla AJ, Ogundoyin OA, Onakoya PA, Nwaorgu OG
  Malignant tumors of the larynx: Clinicopathologic profile and implication for late disease presentation. Niger Med J. 2016 Sep-Oct;57(5):280-285. doi: 10.4103/0300-1652.190596.
•   Fountzilas G, Bamias A, Kalogera-Fountzila A, Karayannopoulou G, Bobos M, Athanassiou E, Kalogeras KT, Tolis C, Tsekeris P, Papakostas P, Vamvouka C, Zaramboukas T, Kosmidis P, Zamboglou N, Misailidou D
  Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res. 2009 Feb;29(2):529-38.
•   Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D
  MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. J Oncol. 2009;2009:305908. doi: 10.1155/2009/305908. Epub 2009 Dec 29.
•   Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P
  Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007 Jul 1;13(13):3855-9. doi: 10.1158/1078-0432.CCR-07-0252.
•   Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE
  ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res. 2011 Dec;31(12):4135-9.
•   Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A, Robinson RA
  Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13. doi: 10.1097/01.mlg.0000236095.97947.26.
•   Jiang C, Guo Y, Li Y, Kang J, Sun X, Wu H, Feng J, Xu Y
  The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer. J Thorac Dis. 2021 May;13(5):3126-3136. doi: 10.21037/jtd-21-755. Erratum In: J Thorac Dis. 2022 Mar;14(3):797-798.
•   Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K
  ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008 Jul 8;99(1):167-72. doi: 10.1038/sj.bjc.6604464.
•   Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, Kim CW, Kim KH, Heo DS
  Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2009 Aug;20(8):1414-9. doi: 10.1093/annonc/mdp002. Epub 2009 May 25.
•   Langer CJ
  Exploring biomarkers in head and neck cancer. Cancer. 2012 Aug 15;118(16):3882-92. doi: 10.1002/cncr.26718. Epub 2012 Jan 26. Erratum In: Cancer. 2012 Dec 1;118(23):6014.
•   Li FY, Ren XB, Xie XY, Zhang J
  Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer. Asian Pac J Cancer Prev. 2013;14(12):7203-6. doi: 10.7314/apjcp.2013.14.12.7203.
•   Markou K, Christoforidou A, Karasmanis I, Tsiropoulos G, Triaridis S, Constantinidis I, Vital V, Nikolaou A
  Laryngeal cancer: epidemiological data from Nuorthern Greece and review of the literature. Hippokratia. 2013 Oct;17(4):313-8.
•   Nocini R, Molteni G, Mattiuzzi C, Lippi G
  Updates on larynx cancer epidemiology. Chin J Cancer Res. 2020 Feb;32(1):18-25. doi: 10.21147/j.issn.1000-9604.2020.01.03.
•   Vilmar A, Sorensen JB
  Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19.

Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.

Details for clinical trial NCT05832593